Back to Semaglutide research
semaglutide glp 1 agonist other 2026-04-11 EuropePMC

UK Biobank Study Uncovers Key Drivers of Hip and Knee Osteoarthritis

A comprehensive descriptive analysis of hip and knee radiographic osteoarthritis in the UK Biobank in relation to joint pain, joint site interrelationships, obesity, race and deprivation: Findings fro

Background

Osteoarthritis (OA) is a debilitating, chronic condition causing pain and limiting mobility, affecting over 565 million people globally. Its prevalence is projected to increase by 60-100% by 2050, driven by an aging population and rising obesity rates, which account for approximately 20% of OA cases. Despite known risk factors like age, obesity, genetics, and socioeconomic deprivation, there's a critical need for current, comprehensive epidemiological data on OA from large, contemporary population cohorts to better understand its complex risk profile.


semaglutide glp 1 agonist
Source: europepmc:epmc_PMC13015658 · Ingested 2026-04-11 · Digest: gemini-2.5-flash